Cue Biopharma is trading 6.3% higher after hours at $20.80, with no confirmed company-specific catalyst. - On October 13, shares fell 20.48% during the regular session to $19.57 before rebounding after hours. - The investor-relations page lists positive CUE-221 Phase 2 results dated September 20; B. Riley’s Buy rating was reported October 13. Neither is established as the cause of the after-hours move. - The Nasdaq fell 2.11% during the session, offering no clear explanation for the gain.